Mersana Therapeutics (MRSN) Competitors $7.14 -0.33 (-4.42%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.20 +0.06 (+0.77%) As of 04:52 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRSN vs. HURA, CGEN, GNLX, MGNX, ZNTL, PLX, BHST, IKT, SKYE, and TARAShould you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include TuHURA Biosciences (HURA), Compugen (CGEN), Genelux (GNLX), MacroGenics (MGNX), Zentalis Pharmaceuticals (ZNTL), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), Inhibikase Therapeutics (IKT), Skye Bioscience (SKYE), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Mersana Therapeutics vs. Its Competitors TuHURA Biosciences Compugen Genelux MacroGenics Zentalis Pharmaceuticals Protalix BioTherapeutics BioHarvest Sciences Inhibikase Therapeutics Skye Bioscience Protara Therapeutics Mersana Therapeutics (NASDAQ:MRSN) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Which has more risk and volatility, MRSN or HURA? Mersana Therapeutics has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Do institutionals & insiders believe in MRSN or HURA? 93.9% of Mersana Therapeutics shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 13.0% of Mersana Therapeutics shares are held by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer MRSN or HURA? In the previous week, TuHURA Biosciences had 1 more articles in the media than Mersana Therapeutics. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 1.45 beat TuHURA Biosciences' score of 1.08 indicating that Mersana Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Mersana Therapeutics Positive TuHURA Biosciences Positive Is MRSN or HURA more profitable? TuHURA Biosciences has a net margin of 0.00% compared to Mersana Therapeutics' net margin of -212.94%. TuHURA Biosciences' return on equity of -248.79% beat Mersana Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mersana Therapeutics-212.94% -990.16% -54.85% TuHURA Biosciences N/A -248.79%-150.83% Which has stronger valuation & earnings, MRSN or HURA? TuHURA Biosciences has lower revenue, but higher earnings than Mersana Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMersana Therapeutics$40.50M0.88-$69.19M-$14.62-0.49TuHURA BiosciencesN/AN/A-$21.68MN/AN/A Do analysts recommend MRSN or HURA? Mersana Therapeutics currently has a consensus price target of $56.60, indicating a potential upside of 692.72%. TuHURA Biosciences has a consensus price target of $12.67, indicating a potential upside of 406.67%. Given Mersana Therapeutics' higher possible upside, equities research analysts plainly believe Mersana Therapeutics is more favorable than TuHURA Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mersana Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 SummaryMersana Therapeutics beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks. Get Mersana Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRSN vs. The Competition Export to ExcelMetricMersana TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.63M$3.15B$5.78B$10.18BDividend YieldN/A2.32%5.73%4.60%P/E Ratio-0.4921.5775.5726.02Price / Sales0.88254.90461.9291.11Price / CashN/A44.4425.8129.91Price / Book-3.729.6112.526.25Net Income-$69.19M-$53.29M$3.29B$270.76M7 Day Performance1.42%0.57%0.78%2.54%1 Month Performance-0.28%4.56%4.56%5.73%1 Year Performance-86.46%10.44%66.82%25.85% Mersana Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRSNMersana Therapeutics4.0642 of 5 stars$7.14-4.4%$56.60+692.7%-86.5%$35.63M$40.50M-0.49150Positive NewsGap DownHURATuHURA Biosciences1.8724 of 5 stars$2.52-1.2%$12.67+402.6%N/A$127.62MN/A0.00N/ACGENCompugen1.7155 of 5 stars$1.45+1.4%$4.00+175.9%-32.0%$127.61M$27.86M-6.5970Positive NewsGNLXGenelux1.5723 of 5 stars$3.56+5.6%$20.33+471.2%+61.9%$127.30M$10K-4.1410Positive NewsHigh Trading VolumeMGNXMacroGenics4.4778 of 5 stars$1.76-12.0%$3.60+104.5%-57.0%$126.41M$149.96M-3.09430Positive NewsZNTLZentalis Pharmaceuticals1.998 of 5 stars$1.63-6.9%$8.20+403.1%-54.0%$126.24M$67.43M-0.72160Positive NewsPLXProtalix BioTherapeutics2.3244 of 5 stars$1.58+2.6%$15.00+849.4%+72.4%$125.98M$61.95M-12.15200High Trading VolumeBHSTBioHarvest Sciences2.4229 of 5 stars$7.14-5.9%$13.67+91.4%N/A$124.67M$25.19M-10.20N/AGap UpIKTInhibikase Therapeutics0.0063 of 5 stars$1.66-0.6%N/AN/A$124.44M$260K0.006SKYESkye Bioscience2.0515 of 5 stars$4.12+3.0%$15.50+276.2%-29.2%$123.95MN/A-3.8911TARAProtara Therapeutics1.7335 of 5 stars$3.07-2.5%$19.60+538.4%+67.0%$121.53MN/A-1.9030 Related Companies and Tools Related Companies HURA Competitors CGEN Competitors GNLX Competitors MGNX Competitors ZNTL Competitors PLX Competitors BHST Competitors IKT Competitors SKYE Competitors TARA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRSN) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mersana Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mersana Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
